Express Scripts Holding Co (ESRX)

ESRX (NASDAQ:Health Services) EQUITY
$82.38
pos +0.00
+0.00%
Today's Range: 82.31 - 83.35 | ESRX Avg Daily Volume: 3,667,900
Last Update: 03/27/15 - 4:00 PM EDT
Volume: 0
YTD Performance: -2.70%
Open: $0.00
Previous Close: $82.99
52 Week Range: $64.64 - $88.83
Oustanding Shares: 726,898,000
Market Cap: 60,482,521,360
6-Month Chart
TheStreet Ratings Grade for ESRX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 12 12
Moderate Buy 3 3 3 3
Hold 6 6 5 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.73 1.73 1.63 1.55
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 31.44
Price Earnings Comparisons:
ESRX Sector Avg. S&P 500
31.44 31.40 27.26
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-3.91% 9.46% 54.82%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 1.19 0.29
Net Income 8.70 0.60 0.17
EPS 17.90 0.05 0.02
Earnings for ESRX:
EBITDA 5.85B
Revenue 100.89B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $1.10 $1.36 $5.44 $6.02
Number of Analysts 14 13 17 16
High Estimate $1.14 $1.39 $5.49 $6.15
Low Estimate $1.08 $1.32 $5.37 $5.92
Prior Year $0.99 $1.23 $4.88 $5.44
Growth Rate (Year over Year) 11.18% 10.82% 11.38% 10.76%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Update
Feb 25, 2015 | 6:55 AM EST
ESRX - Express Scripts Holding Co Investor Meeting - 8:30AM St. Louis, MO
Watch this leadership group that's been lagging.
Bearish
Jan 28, 2015 | 6:42 AM EST
ESRX was downgraded from Outperform to Market Perform, FBR Capital Markets said. Valuation call, as the company lacks near-term catalys...

Why I'm Sticking With Biotech Real Money Pro($)

They offer a nice shelter for the headwinds now hitting equities.
Its hepatitis C drug will dominate the market.

Gilead Is a Buying Opportunity Real Money Pro($)

Its hepatitis C drug is better; the stock trades at a discount.
Here's the best way to play them.
Stocks that do well when the economy rises are shining.

In Defense of Gilead Sciences Real Money Pro($)

It has a great long-term future.
It might be good for consumers, but not for the stock.

Columnist Conversations

Google rallied off its 2012 low making a series of higher highs and higher lows for two years. The pullback to...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.